The Law Offices of Frank R. Cruz announces an investigation of Annovis Bio, Inc. (“Annovis” or the “Company”) (NYSE: ANVS) on behalf of investors concerning the Company’s possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On July 28, 2021, after the market closed, Annovis reported that Posiphen failed to show statistical significance in treating Alzheimer's and Parkinson's patients relative to a placebo.

On this news, the Company's stock price fell $65.94 per share, or over 60%, to close at $43.50 per share on July 29, 2021, thereby injuring investors.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased Annovis securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210803006079/en/

The Law Offices of Frank R. Cruz Announces Investigation of Annovis Bio, Inc. (ANVS) on Behalf of Investors